GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...
Seeking Alpha's Quant system consistently outperforms the S&P 500 ( SP500 ), driven by powerful computer processing and SA's ...
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.
In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.
Begin your TipRanks Premium journey today. Eli Lilly & Co (LLY) Company Description: Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical ...
Eli Lilly and Company (LLY) is a global leader in healthcare ... medicines to address some of the world's most pressing medical needs. With a market cap of $759.4 billion, Eli Lilly operates ...
In this article, we are going to take a look at where Eli Lilly and Company (NYSE ... ll have a lot of winners with these drug and medical device plays.” For this article, we compiled a list ...
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...